Myomo Inc（MYO）財務資料MYOMyomo Inc

Myomo Inc (MYO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Direct to patient, accounting for 70.9% of total sales, equivalent to $7.17M. Another important revenue stream is Clinical/Medical providers. Understanding this composition is critical for investors evaluating how MYO navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Myomo Inc maintains a gross margin of 72.13%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -19.26%, while the net margin is -34.36%. These profitability ratios, combined with a Return on Equity (ROE) of -123.76%, provide a clear picture of how effectively MYO converts its operational activities into shareholder value.

In the context of the broader market, MYO competes directly with industry leaders such as OGCP and MEDS. With a market capitalization of $48.13M, it holds a significant position in the sector. When comparing efficiency, MYO's gross margin of 72.13% stands against OGCP's N/A and MEDS's -9.80%. Such benchmarking helps identify whether Myomo Inc is trading at a premium or discount relative to its financial performance.

Myomo reported a Q2 revenue of $11.7 million, a 21% increase year-over-year, with a gross margin of 72.1%, up from 62.7% in the previous year. However, the company continues to report net losses, with a net income of -$4.0 million in Q2 2026.